Argent Biopharma (AU:RGT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent BioPharma has successfully raised an additional US$2 million through the issue of 2.5 million shares, bolstering their efforts to progress drug development programs, including CannEpil® and CimetrA®, in the US and EU markets. The placement included an attractive incentive of free warrants for investors, with the new shares issued at a significant premium to the recent average share price.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.